1 therapies2020-04-22T15:04:35+00:00

treatment of depression and chronic pain

Sooma tDCS™ is a medical device used by healthcare professionals worldwide. It has acquired e.g. CE, Health Canada, MDA, HSA, TGA and COFEPRIS approvals. The devices are manufactured in Finland under ISO 13485.

Healthcare professional – Request a quote >

How it works

The success of Sooma therapies is built on our Sooma tDCS™ device, which is a portable stimulation unit with industry leading ease of use. With Comfort accessories, the stimulation is provided with unparalleled patient comfort and accuracy. Our cloud-based Sooma Online platform enables a healthcare professional to stay in control of the therapy even when it is applied at patients’ home.

One treatment session takes 20 to 30 minutes and it is repeated once-a-day for several weeks.

Check out the latest white paper (pdf)

News and updates

2406, 2019

Treatment outcomes (2019)

During the last 20 years, the efficacy and safety of transcranial direct current stimulation (tDCS) in various indications have been studied. One of the most studied indications is Major Depressive Disorder (MDD), for which the efficacy and safety of tDCS has been proven through much research: The Royal College of Psychiatrists gave out a statement about the [...]

1101, 2019

Official Press Release – Sooma Medical Awarded US Patent for Advanced Stimulation Electrode.

Official Press Release - Sooma Medical Awarded US Patent for Advanced Stimulation Electrode. Helsinki, Finland, January 11, 2019 (Newswire.com) - Sooma Medical announces receipt of a U.S. patent for it's new stimulation electrode. The electrode technology is essential for safe and effective delivery of all neuromodulation therapies. The electrode technology developed by Sooma R&D team dramatically reduces the resistance in [...]

Meet us at the following conferences and events

Woman sitting on a pier with Sooma hat

Frequently asked questions

The effect of Sooma therapies are based on subtle adjustments of the brain function using a small electrical current. The therapy is targeted to the relevant neuronal pathways e.g. dorsolateral prefrontal cortex for depression in order to achieve a treatment response.

The main changes following the therapy happen at the cortical level of the brain and can be detected with e.g. EEG and fMRI. Recently, also changes in the deep brain regions have also been detected by the use of implanted electrodes.

Sooma therapies are provided by a prescription only. They can be used to augment medication or psychotherapy, or as a monotherapy in first-line treatment. Patients who do not get adequate response from medication, or have trouble tolerating them, may benefit significantly from Sooma therapies.

There are no serious side-effects reported in 20 years of scientific study. The main side-effects are local and transient such as skin itching, mild headache or redness under the treatment area.

Sooma therapies are contraindicated from patients with

  1. Metal implants inside the skull
  2. Cardiac pacemakers
  3. Acute eczema or broken skin in the intended stimulation area

Sooma therapies are widely available around the world. First, you must be evaluated by a doctor to ensure that this is a safe and appropriate treatment for you. If your doctor is not familiar with Sooma therapies, you may request us to get in contact with your doctor by pressing “Contact Us”.


  1. Sooma Treatment Outcomes (2018). Available online: https://soomamedical.com/blog/treatment-outcomes-2/
  2. Zhu CE et al. Effiectiveness and safety of transcranial direct current stimulation in fibromyalgia: A systematic review and meta-analysis. J Rehabil Med. 2017 Jan 19;49(1):2-9.
  3. Cruccu G et al. EAN guidelines on central neurostimulation therapy in chronic pain conditions. Eur J Neurol. 2016 Oct;23(10):1489-99.
  4. Bikson M, et al. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul. 2016 Sep-Oct;9(5):641-61.
Logo of CE-marking
Quality Management System (ISO 13485) logo